Laidlaw initiated coverage on shares of AltheaDx (NASDAQ:IDGX) in a research report report published on Thursday, The Fly reports. The brokerage issued a buy rating on the stock.
AltheaDx, Inc is a United States-based commercial-stage molecular diagnostics company. The Company is specialized in the field of pharmacogenetics. The Company focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients.
Receive News & Ratings for AltheaDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AltheaDx and related companies with MarketBeat.com's FREE daily email newsletter.